Tradename | Company | Number | Date | Products |
---|---|---|---|---|
REGLAN | ANI Pharmaceuticals | N-017854 RX | 1982-01-01 | 2 products, RLD, RS |
GIMOTI | Evoke Pharma | N-209388 RX | 2020-06-19 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
gimoti | New Drug Application | 2021-01-07 |
metoclopramide | ANDA | 2025-01-15 |
metoclopramide hydrochloride | ANDA | 2024-10-22 |
reglan | New Drug Application | 2020-06-19 |
Code | Description |
---|---|
J2765 | Injection, metoclopramide hcl, up to 10 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Vomiting | D014839 | HP_0002013 | R11.1 | — | — | 1 | 2 | — | 3 |
Nausea | D009325 | HP_0002018 | R11.0 | — | — | 1 | 1 | — | 2 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | 1 | — | 1 |
Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | — | 1 | — | 1 |
Headache | D006261 | HP_0002315 | R51 | — | — | — | 1 | — | 1 |
Drug common name | Metoclopramide |
INN | metoclopramide |
Description | Metoclopramide is a member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine. It has a role as an antiemetic, a dopaminergic antagonist, a gastrointestinal drug, a xenobiotic and an environmental contaminant. It is a tertiary amino compound, a substituted aniline, a member of benzamides and a member of monochlorobenzenes. It is a conjugate base of a metoclopramide(1+). |
Classification | Small molecule |
Drug class | D2 receptor antagonist; 5-HT3 receptor antagonist; 5-HT4 receptor agonist; Prolactin releaser |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC |
PDB | — |
CAS-ID | 364-62-5 |
RxCUI | — |
ChEMBL ID | CHEMBL86 |
ChEBI ID | 107736 |
PubChem CID | 4168 |
DrugBank | DB01233 |
UNII ID | L4YEB44I46 (ChemIDplus, GSRS) |